ES2076141T3 - 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos. - Google Patents

5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.

Info

Publication number
ES2076141T3
ES2076141T3 ES87118728T ES87118728T ES2076141T3 ES 2076141 T3 ES2076141 T3 ES 2076141T3 ES 87118728 T ES87118728 T ES 87118728T ES 87118728 T ES87118728 T ES 87118728T ES 2076141 T3 ES2076141 T3 ES 2076141T3
Authority
ES
Spain
Prior art keywords
triazol
anticonvulsives
onas
aril
anticonvulsants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87118728T
Other languages
English (en)
Inventor
Francis P Miller
John M Kane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2076141T3 publication Critical patent/ES2076141T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Lubricants (AREA)

Abstract

ESTA INVENCION SE REFIERE A 5-ARIL-3H-1,2,4-TRIAZOL-3-ONAS Y SU USO COMO ANTICONVULSIVOS PARA EL TRATAMIENTO DE TRASTORNOS EPILEPTOIDES.
ES87118728T 1986-12-19 1987-12-17 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos. Expired - Lifetime ES2076141T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94463486A 1986-12-19 1986-12-19
US9031087A 1987-08-27 1987-08-27

Publications (1)

Publication Number Publication Date
ES2076141T3 true ES2076141T3 (es) 1995-11-01

Family

ID=26782142

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87118728T Expired - Lifetime ES2076141T3 (es) 1986-12-19 1987-12-17 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.

Country Status (10)

Country Link
EP (1) EP0273310B1 (es)
JP (1) JP2542880B2 (es)
KR (1) KR960003326B1 (es)
AT (1) ATE123942T1 (es)
DE (1) DE3751362T2 (es)
DK (1) DK172661B1 (es)
ES (1) ES2076141T3 (es)
GR (1) GR3017358T3 (es)
IE (1) IE66265B1 (es)
PH (1) PH24094A (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966909A (en) * 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
DE19816882A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
ES2391461T3 (es) 2004-07-27 2012-11-27 F. Hoffmann-La Roche Ag Compuestos de benciltriazolona utilizados como inhibidores no nucleósidos de transcriptasa inversa
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
MX2009009920A (es) 2007-03-29 2009-10-19 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
MX376108B (es) 2012-12-20 2025-03-07 Tempest Therapeutics Inc Compuestos de triazolona y usos de los mismos.
AU2014315151A1 (en) 2013-09-06 2016-03-03 Inception 2, Inc. Triazolone compounds and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1126882B (de) * 1960-05-03 1962-04-05 Boehringer Sohn Ingelheim Verfahren zur Herstellung von 1,2,4-Triazolonen-(5)
BE621842A (es) * 1962-08-27
DE1545646B1 (de) * 1965-12-15 1969-09-18 Boehringer Sohn Ingelheim 1,3-Dimethyl-4-(2',4'-dichlorphenyl)-1,2,4-triazolon-(5) und Verfahren zu dessen Herstellung
DD153953A3 (de) * 1980-04-01 1982-02-17 Gottfried Schuster Mittel zur chemotherapie von virosen der kulturpflanzen
DD160447A1 (de) * 1981-03-26 1983-08-03 Johannes Dost Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten
AR243171A1 (es) * 1985-10-29 1993-07-30 Merrell Pharma Inc Procedimiento para preparar 5-aril-2,4-dialquil-3h-1,2,4-triazol-3-tionas.

Also Published As

Publication number Publication date
KR880007494A (ko) 1988-08-27
ATE123942T1 (de) 1995-07-15
DK671087D0 (da) 1987-12-18
EP0273310B1 (en) 1995-06-21
PH24094A (en) 1990-03-05
JP2542880B2 (ja) 1996-10-09
EP0273310A2 (en) 1988-07-06
IE873458L (en) 1988-06-19
EP0273310A3 (en) 1991-01-09
KR960003326B1 (ko) 1996-03-08
DK671087A (da) 1988-06-20
JPS63170313A (ja) 1988-07-14
DE3751362D1 (de) 1995-07-27
DE3751362T2 (de) 1996-02-29
DK172661B1 (da) 1999-05-03
GR3017358T3 (en) 1995-12-31
IE66265B1 (en) 1995-12-27

Similar Documents

Publication Publication Date Title
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
MX9101913A (es) Derivados de quinazolinas para potenciar la actividad antitumoral
ATE35416T1 (de) Derivate des glycerophosphocholins und glycerophosphoethanolamins, ihre herstellung und verwendung.
DE3889416D1 (de) Wärmebeständiges Schmiermittel zur Behandlung von Kunstfasern.
DE3789530D1 (de) Klonierung und Expression des sauren Fibroblastenwachstumsfaktors.
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
PH24094A (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
DK67683A (da) Fremgangsmaade til fremstilling af 2,3-diaryl-5-halogen-thio-phener
FI873428A7 (fi) Silmälääketieteelliset koostumukset hermodegeneraatioiden hoitoon.
IT8420213A0 (it) Procedimento per la preparazione di 1,8-diidrossi-10-acil-9-antroni, in particolare per l'uso nel trattamento di psoriasi.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
ES2069528T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso en el tratamiento de trastornos neurodegenerativos.
DE3576689D1 (de) Oxa- und thiadiazolylderivate und ihre verwendung.
EP0116628A4 (en) 1-ACYL-3-PYRIDYLMETHYLGUANIDINE AND THEIR USE AS AN ANI-HYPERTENSIVE.
DE3767175D1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
ES2056876T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
DE3872916D1 (de) Herstellung und reinigung eines n,n-diethylaminophenols.
DE3776488D1 (es)
ATE90562T1 (de) Antiepileptisch wirkende pyrazolopyridine.
PT1017377E (pt) Utilizacao de 2-aminotetralinas 6,7-substituidas para o tratamento de condicoes inflamatorias mediadas por citoquina
FI871737A0 (fi) Kraftanlaeggning med foerbraenning i en fluidiserad baedd.
ATE49964T1 (de) Benzodioxepane, verfahren zur herstellung und verwendung als heilmittel.
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.
ATE95061T1 (de) Schmiermittelzubereitung zur behandlung von rheuma.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 273310

Country of ref document: ES